RedHill Biopharma (RDHL) Reports Q4 Loss of $0.04/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to RedHill Biopharma (RDHL) Reports Q4 Loss of $0.04/Share

RedHill Biopharma Reports 2016 First Quarter Financial Results

April 20, 2016 7:44 AM EDT

RedHill maintains a strong and debt-free balance sheet with approximately $53 million in cash at the end of the first quarter, allowing the Company to continue to diligently execute its strategic and operational plans, including its three ongoing Phase III gastrointestinal disease programs in the U.S.             Key milestones in the first quarter of 2016 include:              Initiation of a Phase II study with BEKINDA for diarrhea-predominant irritable bowel syndrome (IBS-D)Receipt of encouraging top-line interim results from a Phase IIa study with RHB-104 for multiple... More